A diminution of Δ9-tetrahydrocannabinol modulation of dynorphin A-(1- 17) in conjunction with tolerance development

European Journal of Pharmacology

Volumn 381, Issue 2-3, 1999, Pages 105-111

  Mason Jr , David J ^a   Lowe, John ^b   Welch, Sandra P ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

9 tetrahydrocannabinol; Antinociception; Dynorphin A; Opioid; Tail flick latency

Indexed keywords

DRONABINOL; DYNORPHIN A; ANALGESIC AGENT; DYNORPHIN; KAPPA OPIATE RECEPTOR; SUBSTANCE P; TETRAHYDROCANNABINOL;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; DESENSITIZATION; DOSE RESPONSE; DRUG RECEPTOR BINDING; DRUG TOLERANCE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TAIL FLICK TEST; ANIMAL; CEREBROSPINAL FLUID; DRUG EFFECT; INTRASPINAL DRUG ADMINISTRATION; METABOLISM; RADIOIMMUNOASSAY; REACTION TIME; SPRAGUE DAWLEY RAT;

ANALGESICS; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; DYNORPHINS; INJECTIONS, SPINAL; MALE; RADIOIMMUNOASSAY; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME; RECEPTORS, OPIOID, KAPPA; SUBSTANCE P; TETRAHYDROCANNABINOL;

EID: 0032589582     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00542-7     Document Type: Article

References (14)

1. 9-THC without alteration of cannabinoid binding or mRNA levels in the whole brain. Pharmacol. Biochem. Behav. 46:1993;575-579.
2. D'Amour F.E., Smith D.L. A method for determining loss of pain sensation. J. Pharmacol. Exp. Ther. 72:1941;74-79.
3. 9-tetrahydrocannabinol on the hypothalamo-hypophyseal-adrenal axis of rats. Eur. J. Pharmacol. 12:1970;382-384.
4. Dunnett C.W. A multiple comparison procedure for comparing several treatments with a control. J. Am. Stat. Assoc. 50:1955;1096-1121.
5. Harris L.S., Pierson A.K. Some narcotic antagonists in the benzomorphan series. J. Pharmacol. Exp. Ther. 143:1964;141-148.
6. 2 noradrenergic mechanism. Brain Res. 559(2):1991;309-314.
7. 9-Tetrahydrocannabinol tissue and subcellular distribution in the central nervous system and tissue distribution in peripheral organs of tolerant and non-tolerant dogs. J. Pharmacol. Exp. Ther. 196:1976;128-144.
8. Oveido A., Glowa J., Herkenham M. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study. Brain Res. 616:1993;293-302.
9. 9-tetrahydrocannabinol treatment. Pharmacol. Biochem. Behav. 47:1994;33-40.
10. 9-tetrahydrocannabinol. Pharmacol. Biochem. Behav. 51:1995;731-737.
11. Siemans A.J., Kalant H. Metabolism of delta-1-tetrahydrocannabinol by rats tolerant to cannabis. Can. J. Physiol. Pharmacol. 52:1974;1154-1166.
12. Tseng L.F. Intracerebroventricular administration of beta-endorphin releases immunoreactive methionine enkephalin from the spinal cord of cats, guinea pigs and mice. Neuropharmacology. 28:1989;1333-1339.
13. 9-THC precipitated by a cannabinoid receptor antagonist. Eur. J. Pharmacol. 280:1995;R13-R15.
14. Yaksh T.L. The antinociceptive effect of intrathecally administered levonantradol and desacetyllevonantradol in the rat. J. Clin. Pharmacol. 21:1981;334-340.